TAIWAN ETF COMPARISON
00898 vs 00919
Solactive Global Genomics Immunology and medical revolution index compared with CAPITAL TIP CUSTOMIZED TAIWAN SELECT HIGH DIVIDEND EXCHANGE TRADED FUND.
Four ways to read this comparison
Portfolio similarity, historical return, distribution yield and annual fund cost answer different questions.
Price and return trend
Normalized returns make funds with different unit prices comparable. Switch to price mode to view actual TWD prices.
Key metrics
| Metric | 00898 Solactive Global Genomics Immunology and medical revolution index | 00919 CAPITAL TIP CUSTOMIZED TAIWAN SELECT HIGH DIVIDEND EXCHANGE TRADED FUND |
|---|---|---|
| Latest close | TWD 9.53 | TWD 29.57 |
| Assets under management | TWD 1.3B | TWD 514.9B |
| Beneficiaries | 10,227 | 1,375,210 |
| Trailing 12-month distribution yield | — | 9.67% |
| Total expense ratio | — | — |
| Management fee | 0.85% | 0.30% |
| Custody fee | 0.20% | 0.04% |
Performance and risk
| Metric | 00898 | 00919 |
|---|---|---|
| 1-year return | +46.39% | +52.25% |
| 3-year return | +21.09% | +81.28% |
| 5-year return | — | — |
| 1-year volatility | 22.66% | 18.08% |
| 1-year max drawdown | -10.20% | -10.49% |
| 1-year Sharpe ratio | 1.92 | 2.09 |
Returns are price returns. Risk statistics use the available one-year price history and are shown only when sufficient observations exist.
Sector allocation
Weights are based on the latest available disclosed portfolios.
Common holdings
0 securities appear in both disclosed portfolios. Data updated Jul 30, 2026.
No data is currently available.
Holdings unique to each ETF
These securities appear in one disclosed portfolio but not the other.
| # | Security | 00898 weight |
|---|---|---|
| 1 | WGS US · GENEDX HOLDINGS CORP | 3.84% |
| 2 | NTRA US · NATERA INC | 3.54% |
| 3 | BLLN US · BILLIONTOONE INC. | 3.32% |
| 4 | ABBV US · AbbVie Inc. | 3.12% |
| 5 | TWST US · TWIST BIOSCIENCE CORP | 3.12% |
| 6 | TXG US · 10X GENOMICS INC | 3.08% |
| 7 | GH US · GUARDANT HEALTH INC | 2.94% |
| 8 | IOVA US · IOVANCE BIOTHERAPEUTICS INC | 2.92% |
| 9 | LLY US · ELI LILLY & CO | 2.87% |
| 10 | 9969 HK · INNOCARE PHARMA LTD | 2.72% |
| 11 | CRSP US · CRISPR THERAPEUTICS AG | 2.59% |
| 12 | VRTX US · VERTEX PHARMACEUTICALS INC | 2.56% |
| 13 | ARWR US · ARROWHEAD PHARMACEUTICALS INC | 2.53% |
| 14 | 1548 HK · GENSCRIPT BIOTECH CORP | 2.52% |
| 15 | PFE US · Pfizer Inc | 2.51% |
| 16 | BIIB US · BIOGEN INC | 2.36% |
| 17 | GILD US · Gilead Sciences Inc | 2.34% |
| 18 | REGN US · REGENERON PHARMACEUTICALS | 2.34% |
| 19 | MRK US · Merck & Co Inc | 2.22% |
| 20 | BNTX US · BIONTECH SE | 2.19% |
| 21 | JNJ US · Johnson & Johnson | 2.18% |
| 22 | VKTX US · VIKING THERAPEUTICS INC | 2.17% |
| 23 | RXRX US · RXRX.OQ | 2.03% |
| 24 | NTLA US · INTELLIA THERA CS | 2.02% |
| 25 | QGEN US · QIAGEN NV | 1.83% |
Fund profile and disclosure dates
| Metric | 00898 | 00919 |
|---|---|---|
| Issuer | Cathay Securities Investment Trust | Capital Investment Trust |
| Tracking index / benchmark | — | — |
| Listing date | Nov 22, 2021 | Oct 20, 2022 |
| Latest market date | Jul 31, 2026 | Jul 31, 2026 |
| Holdings date | Jul 29, 2026 | Jul 30, 2026 |
| Eligible stock positions | 49 | 40 |
| Premium / discount | +0.21% | -0.03% |
Switching estimate
Estimate how many units of the other ETF the current market value could purchase.
0089800919
Current market valueTWD 95.3K
Unrealized gain / lossTWD 0
Estimated 00919 units3,222
Estimated annual distribution changeTWD 9.2K
This estimate excludes brokerage fees, taxes, bid-ask spreads and intraday price movement.
Continue researching this pair
Review each ETF independently or open another published comparison.
Taiwan ETF comparison FAQ
What does portfolio overlap measure?
For each common security, ETF Info takes the smaller of the two portfolio weights and adds those amounts. A higher percentage indicates more similar disclosed stock allocation.
Are historical returns shown with distributions?
Use the label shown for each metric. The long-period return fields are based on the return dataset, while the interactive price chart shows price returns and excludes distributions.
Can the lower-fee or higher-return ETF be considered the winner?
No single metric determines suitability. Fees, risk, liquidity, tracking exposure, distributions and portfolio construction answer different questions.
How to use this comparison
Fees, historical returns and overlap answer different questions. Portfolio overlap shows how similar the latest disclosed holdings are; it does not predict future performance or account for every trading cost, tax or distribution policy.